These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25895634)

  • 1. Pharmacological treatment of negative symptoms in schizophrenia.
    Möller HJ; Czobor P
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):567-78. PubMed ID: 25895634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?
    Möller HJ
    Psychiatr Danub; 2016 Dec; 28(4):435-440. PubMed ID: 27855437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials.
    Rummel C; Kissling W; Leucht S
    Schizophr Res; 2005 Dec; 80(1):85-97. PubMed ID: 16183258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the negative symptoms of schizophrenia: new treatment options.
    Möller HJ
    CNS Drugs; 2003; 17(11):793-823. PubMed ID: 12921492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    Buckley PF; Stahl SM
    Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should patients with schizophrenia receive antidepressants?
    Terevnikov V; Stenberg JH; Joffe G
    Duodecim; 2017; 133(5):465-71. PubMed ID: 29205993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of antidepressants in the treatment of negative symptoms of schizophrenia].
    Palomba A; Lodovighi MA; Belzeaux R; Adida M; Azorin JM
    Encephale; 2015 Dec; 41(6 Suppl 1):6S36-40. PubMed ID: 26776391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on New and Emerging Treatments for Schizophrenia.
    Gopalakrishna G; Ithman MH; Lauriello J
    Psychiatr Clin North Am; 2016 Jun; 39(2):217-38. PubMed ID: 27216901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological approaches to treating negative symptoms: a review of clinical trials.
    Arango C; Garibaldi G; Marder SR
    Schizophr Res; 2013 Nov; 150(2-3):346-52. PubMed ID: 23938176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
    Tuominen HJ; Tiihonen J; Wahlbeck K
    Schizophr Res; 2005 Jan; 72(2-3):225-34. PubMed ID: 15560967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunct mirtazapine for negative symptoms of schizophrenia.
    Phan SV; Kreys TJ
    Pharmacotherapy; 2011 Oct; 31(10):1017-30. PubMed ID: 21950644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacology of the negative symptoms: current status and prospects for progress.
    Davis MC; Horan WP; Marder SR
    Eur Neuropsychopharmacol; 2014 May; 24(5):788-99. PubMed ID: 24252823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.
    Veerman SRT; Schulte PFJ; de Haan L
    Drugs; 2017 Sep; 77(13):1423-1459. PubMed ID: 28776162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
    Kantrowitz JT
    CNS Drugs; 2017 May; 31(5):373-388. PubMed ID: 28397113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia.
    Terevnikov V; Joffe G; Stenberg JH
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25991654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.